Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Return to program book search

Session Information

CRS C002 - Dermatologic Drug Safety and Efficacy

Tuition fee and ticket required for admission


Date: Friday, March 21

CME Credits: 3.00

Location: Room 705/707

Time: 9:00 AM - 12:00 PM

Director: Stephen E. Wolverton, MD, FAAD - Handout

  • David R. Adams, MD, PharmD, FAAD - Handout
  • James Q. Del Rosso, DO
  • Kenneth B. Gordon, MD, FAAD
  • Julie Claire Harper, MD, FAAD - Handout
  • Junko Takeshita, MD, PhD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Recognize the major risks that involve dermatologic drugs including drug interactions, cutaneous drug reactions and systemic adverse effects.
  • Discuss whether drugs are truly efficacious for various dermatologic indications.

Clinicians in dermatology are continually challenged to make therapeutic decisions with less than ideal available scientific evidence. This session will focus both on drug safety (drug interactions, cutaneous drug reactions, and systemic adverse effects) and drug efficacy (determining the level of evidence for drug benefits for a given indication). The participants will gain significant educational tools to make wise clinical decisions, even when the literature is far from complete on drugs we utilize for dermatologic conditions, while maximizing both drug safety and efficacy.


  • Wolverton SE (Ed). Comprehensive dermatologic drug therapy. (3rd ed.) Elsevier, London, 2012


Friday, March 21
9:00 AMPotentially significant risks of topical therapy: there is life beyond application site reactions / Dr. Del Rosso
9:25 AMDrug interactions that are potentially life-threatening / Dr. Wolverton
9:50 AMTo prescribe or not to prescribe: evaluating the evidence for drug efficacy / Dr. Takeshita
10:15 AMPutting drug risks into perspective: examples from isotretinoin therapy / Dr. Harper
10:40 AMAdverse cutaneous drug reactions: some useful cases / Dr. Adams
11:05 AMClarifying the risks of biologic therapy in dermatology / Dr. Gordon
11:30 AMBlack box warnings: how to minimize the risk of these important complications / Dr. Wolverton